Bolt Biotherapeutics, Inc.
BOLT
$5.44
$0.29385.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -62.68% | -67.87% | -2.36% | 35.86% | 64.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -62.68% | -67.87% | -2.36% | 35.86% | 64.64% |
| Cost of Revenue | -32.22% | -19.74% | -8.21% | -1.57% | -5.80% |
| Gross Profit | 25.56% | 9.08% | 9.07% | 6.48% | 13.85% |
| SG&A Expenses | -31.44% | -27.72% | -18.08% | -11.33% | -1.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.42% | -22.39% | -9.69% | -3.02% | -3.59% |
| Operating Income | 27.86% | 15.51% | 10.45% | 6.63% | 9.26% |
| Income Before Tax | 23.35% | -0.51% | 8.79% | 8.71% | 13.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.35% | -0.51% | 8.79% | 8.71% | 13.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.35% | -0.51% | 8.79% | 8.71% | 13.84% |
| EBIT | 27.86% | 15.51% | 10.45% | 6.63% | 9.26% |
| EBITDA | 28.25% | 15.74% | 10.61% | 6.76% | 9.50% |
| EPS Basic | 23.94% | 0.40% | 9.68% | 9.64% | 14.76% |
| Normalized Basic EPS | 26.97% | 14.31% | 9.86% | 8.09% | 13.32% |
| EPS Diluted | 23.94% | 0.40% | 9.68% | 9.64% | 14.76% |
| Normalized Diluted EPS | 26.97% | 14.31% | 9.86% | 8.09% | 13.32% |
| Average Basic Shares Outstanding | 0.80% | 0.91% | 0.99% | 1.02% | 1.04% |
| Average Diluted Shares Outstanding | 0.80% | 0.91% | 0.99% | 1.02% | 1.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |